# Synchronous Colon Adenocarcinoma and Renal Cell Carcinoma: Diagnostic Challenges and Simultaneous Laparoscopic Management in Two Cases

## TL;DR

This paper discusses two rare cases of patients with both colon and kidney cancer diagnosed at the same time and treated with a single laparoscopic surgery.

## Contribution

The novelty lies in presenting simultaneous laparoscopic management of synchronous colon and renal cancers, emphasizing the diagnostic and therapeutic challenges.

## Key findings

- Synchronous colon adenocarcinoma and renal cell carcinoma are rare and often diagnosed during staging.
- Simultaneous laparoscopic surgery for both tumors is feasible and leads to good outcomes.
- There are no established guidelines for managing these synchronous malignancies due to their low incidence.

## Abstract

Background: There is an increasing number of synchronous tumor diagnoses, mainly due to new investigative techniques and diagnostic guidelines. While renal and colonic malignancies are common, synchronous cases remain rare. They are usually diagnosed during the staging work-up performed for the primary cancer. Case Presentation: We share our experience with two cases of synchronous colon adenocarcinoma and renal cell carcinoma. The surgical intervention was performed simultaneously and laparoscopically, with good results and prognosis. Reviewing the literature, we found few studies reporting these synchronous tumors, which reflects their low incidence. Renal tumors are often identified during imaging studies performed for staging colonic tumors, and performing surgical treatment during the same operation is widely accepted. We performed a search of the literature to identify similar cases and to look for associations that can lead to synchronous colonic and renal malignancies. We also wanted to highlight the potential for therapeutic management as a single step, thereby avoiding a second surgical procedure. Conclusions: Synchronous renal and colonic malignancies are rare and are generally sporadic. Due to their rarity, there are no established guidelines, and management can be challenging. Presently, the treatment needs to be individualized based on discussions from the tumor board.